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Abstract
AIM
To counteract/reveal celecoxib-induced toxicity and NO 
system involvement. 
METHODS
Celecoxib (1 g/kg b.w. ip) was combined with therapy 
with stable gastric pentadecapeptide BPC 157 (known 
to inhibit these lesions, 10 µg/kg, 10 ng/kg, or 1 ng/kg 
ip) and L-arginine (100 mg/kg ip), as well as NOS 
blockade [N(G)-nitro-L-arginine methyl ester (L-NAME)] 
(5 mg/kg ip) given alone and/or combined immediately 
after celecoxib. Gastrointestinal, liver, and brain lesions 
and liver enzyme serum values in rats were assessed at 
24 h and 48 h thereafter. 
RESULTS
This high-dose celecoxib administration, as a result of 
NO system dysfunction, led to gastric, liver, and brain 
lesions and increased liver enzyme serum values. The 
L-NAME-induced aggravation of the lesions was notable 
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Basic Study
for gastric lesions, while in liver and brain lesions the 
beneficial effect of L-arginine was blunted. L-arginine 
counteracted gastric, liver and brain lesions. These 
findings support the NO system mechanism(s), both 
NO system agonization (L-arginine) and NO system 
antagonization (L-NAME), that on the whole are behind 
all of these COX phenomena. An even more complete 
antagonization was identified with BPC 157 (at both 24 
h and 48 h). A beneficial effect was evident on all the 
increasingly negative effects of celecoxib and L-NAME 
application and in all the BPC 157 groups (L-arginine 
+ BPC 157; L-NAME + BPC 157; L-NAME + L-arginine 
+ BPC 157). Thus, these findings demonstrated that 
BPC 157 may equally counteract both COX-2 inhibition 
(counteracting the noxious effects of celecoxib on all 
lesions) and additional NOS blockade (equally coun-
teracting the noxious effects of celecoxib + L-NAME). 
CONCLUSION
BPC 157 and L-arginine alleviate gastrointestinal, liver 
and brain lesions, redressing NSAIDs’ post-surgery 
application and NO system involvement.
Key words: BPC 157; Celecoxib; L-arginine; N(G)-nitro-
L-arginine methyl ester; Rats
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: In rats treated with the COX-2 inhibitor 
celecoxib, BPC 157 (given intraperitoneally) coun-
teracted lesion development in the stomach, liver and 
brain. BPC 157 treatment alongside with N(G)-nitro-
L-arginine methyl ester (L-NAME) also attenuated any 
effect of L-NAME that would otherwise have intensified 
the deleterious regular course. Consistently, with 
exacerbation (induced by L-NAME administration) and 
amelioration (due to L-arginine) of gastric, liver and 
brain lesions, L-arginine amelioration prevailed (i.e. , the 
gastric, liver and brain lesions were attenuated) when 
given together with L-NAME (L-NAME + L-arginine), 
an effect further reversed toward a marked beneficial 
effect by the addition of BPC 157 (L-NAME + L-arginine 
+ BPC 157).
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INTRODUCTION
We suggest that celecoxib, a specific COX-2 blocker, 
causes gastrointestinal, liver and brain lesions in rats 
when given in high doses, as has already been shown 
with non-selective nonsteroidal antiinflammatory drugs 
(NSAIDs)[1]. These results should also be related to 
the hitherto undetermined interaction with NO system 
dysfunction as well presenting the role of the NO 
system in gastrointestinal lesions[2,3], liver damage 
and hepatic encephalopathy[4]. These findings would 
correspond to hitherto reported lesions after the use of 
non-selective NSAIDs[5-8]. 
To clarify and combat the side effects of celecoxib, 
we focused on the stable gastric pentadecapeptide 
BPC 157, which is known to counteract lesions induced 
by non-selective NSAIDs[5-8] and to interact with the 
NO system in different models and species[9]. We also 
explored mechanisms behind the protection induced 
by the NO synthetase (NOS) substrate L-arginine and 
the aggravation induced by the NOS blocker N(G)-
nitro-L-arginine methyl ester (L-NAME). 
It was previously shown that celecoxib improved 
gastric lesions[10], induced the regression of preneo-
plastic lesions in the liver[11] and counteracted brain 
lesions and convulsions[12-14].
However, research into celecoxib-induced damage 
showed gastric[15-21] or intestinal lesions[22,23] and 
aggravation of kainic acid-convulsions[24]. Finally, both 
celecoxib and indomethacin prevented the gastro-
protective effects induced by a nitric oxide donor or 
an inducer of nitric oxide synthesis[25]. These findings 
reveal more gastrointestinal lesions, more liver toxicity, 
and more toxicity to the brain as known risks for non-
selective NSAIDs[5-8], which are also associated with 
adverse drug reactions in humans[26,27].
Therefore, these results would define the possible 
liver and brain lesions in the post-application period 
during a course of celecoxib-induced damage. In 
this scenario, the combined application of both of 
the NO agents L-NAME and L-arginine, i.e., the 
application of NOS blockade and an NOS substrate, 
testing the dual significance of NO, would clarify 
eventual therapeutic attempts and resolve possible 
controversies. For example, L-NAME was shown to 
attenuate indomethacin-induced microvascular injuries 
and leakage while L-arginine worked in conjunction 
with indomethacin[28]. 
A likely beneficial effect for the stable gastric 
pentadecapeptide BPC 157 on potential celecoxib-
induced toxicity might be related to NO system 
dysfunction, which follows from consistent evidence[1,9]. 
BPC 157 (as an anti-ulcer peptide that is native and 
stable in human gastric juice) has been designated 
to be a novel mediator of cytoprotection[29] that has 
been implemented in inflammatory bowel disease 
and is in trial now to treat multiple sclerosis[30]. Recent 
reviews[1,9] cover that BPC 157 counteracts COX-1/COX-
2-induced gastric, intestinal, liver and brain lesions[5-8], 
aspirin-prolonged bleeding and thrombocytopenia[31] 
and might prevent and rescue adjuvant arthritis[32]. 
BPC 157 also interacts with the effects of both L-arginine 
and L-NAME-induced aggravation in different models 
and species. Thus, we examined these possible 
therapies and the mechanisms behind them[9].
Consequently, we focused on the disturbances at 
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24 h and 48 h after celecoxib application, including 
identifying any gastrointestinal, liver and brain lesions 
as well as identifying any possible noxious stimuli 
that could further aggravate the existing conditions, 
e.g., the NOS blocker L-NAME, which was given alone 
and combined with celecoxib administration. We also 
focused on possible therapies, including the stable 
gastric pentadecapeptide BPC 157 and the NOS 
substrate L-arginine. 
Furthermore, we should emphasize that the pre-
vious high-dose regimens used to demonstrate the 
toxicity of all non-selective NSAIDs[5-8] were compared 
with µg-ng regimens of BPC 157 as a potential antidote 
to counteract these effects[1] and to examine the safety 
profile of celecoxib. Thus, we consistently used this 
selective NSAID at very high doses that consequently 
markedly exceeded the maximal dose used in 
patients[10]. Likewise, in rats treated with celecoxib, 
both BPC 157 regimens, µg and ng, were also validated 
against the NO-related agents L-NAME and L-arginine, 
which were given either alone and/or in combination. 
MATERIALS AND METHODS
Animals
Male albino Wistar (200 g) rats were used in all the 
experiments (at least 10 rats per experimental group 
and interval). Experiments were approved by the local 
ethics committee and assessed by observers unaware 
of the given treatment.
Drugs
The medications used, without carrier or peptidase 
inhibitor, included pentadecapeptide BPC 157 (a partial 
sequence of the human gastric juice protein BPC that is 
freely soluble in water at pH 7.0 and in saline). It was 
prepared as a peptide with 99% (HPLC) purity (1-des-
Gly peptide was the main impurity, manufactured by 
Diagen, Ljubljana, Slovenia, GEPPPGKPADDAGLV, M.W. 
1419). Celecoxib, L-NAME, and L-arginine (Sigma, United 
States) were prepared as previously described[1,9]. 
Protocol
Celecoxib (1 g/kg) was given intraperitoneally, and 
then immediately, as medications, we intraperitoneally 
administered the stable gastric pentadecapeptide 
BPC 157 (10 µg/kg, 10 ng/kg, 1 ng/kg), L-NAME (5 
mg/kg) and L-arginine (100 mg/kg), while controls 
simultaneously received an equal volume of saline (5 
mL/kg) intraperitoneally.
Gastrointestinal assay
Gastric lesions: Injury severity was assessed 
immediately after sacrifice. The sum of the longest 
lesion’s diameters was assessed as described pre-
viously[5,7,8], and gastric tissues were processed for 
routine microscopy analysis as described previously[5,7,8].
Liver assays - bilirubin and enzyme activity: To 
determine the serum values of aspartate transaminase 
(AST), alanine transaminase (ALT) (IU/L) and total 
bilirubin (µmol/L), blood samples were obtained 
immediately after sacrifice and were centrifuged for 
15 min at 3000 rpm. All tests were measured using an 
Olympus AU2700 analyzer with original test reagents 
(Olympus Diagnostica, Lismeehan, Ireland)[5-8].
Liver lesions: Liver tissue was immediately placed 
in 10% neutral buffered formalin for 24 h and 
subsequently embedded in paraffin. Hematoxylin-eosin-
stained sections were analyzed on three high-power 
fields. The number of nuclei and area of cytoplasm as 
well as their diameter were measured using the ISSA 
program (Vamstec, Zagreb, Croatia), and the number 
of binucleated cells was also counted. Microvesicular 
steatosis was scored from 1-3: 1, less than 20% of 
hepatocytes showing microvesicular steatosis; 2, 
20%-60% of hepatocytes showing microvesicular 
steatosis; and 3, over 60% of hepatocytes showing 
microvesicular steatosis. Parenchymal necrosis, 
eosinophilic cytoplasm, pyknotic nuclei and conspicuous 
nucleoli were scored semiquantitatively as follows: 0, 
showing no changes; 1, minimum; 2, moderate; and 3, 
maximum changes[5-8]. 
Brain assay
brain lesions: Brains were fixed in 10% formalin 
for two days. Upon fixation, the brain was grossly 
inspected and cut into consecutive coronal sections. 
Brain slabs were dehydrated in graded ethanol and 
embedded in paraffin. Paraffin blocks were cut into 
5-µm slices. Paraffin slices were deparaffinated in 
xylene, rehydrated in graded ethanol and stained with 
hematoxylin and eosin. The intensity and distribution 
of brain lesions (balloonized or red neurons), brain 
edema and cyanosis were described and evaluated 
semiquantitatively on two scales as follows where 0 
generally indicated no changes: 0-3, edema (1, weakly 
diffuse and/or perifocal; 2, moderate; and 3, strong 
and generalized); 0-4, balloonized or red neurons (1, 
5%; 2, 5%-30%; 3, 30%-50%; and 4, > 50%)[5-8].
Statistical analyses
Statistical analyses of the quantified data were per-
formed by analysis of variance (ANOVA). Post hoc 
comparisons were appraised using the conservative 
Bonferroni/Dunn test. Data are presented as the 
mean ± SD. Non-parametric statistical analyses were 
performed for categorical data using the Kruskal-
Wallis and post hoc Mann-Whitney U test. Values are 
expressed as min/med/max. Values of P < 0.05 were 
considered statistically significant.
RESULTS
Gastric lesions
Celecoxib induced severe gastric lesions (histologically, 
they appeared as mucosal defects ranging from one 
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liver lesions. A stronger beneficial effect occurred 
with BPC 157. BPC 157 alone completely alleviated 
celecoxib-induced liver lesions, both at 24 h and 48 
h. In combination with the other agents, BPC 157 
consistently demonstrated the same beneficial effect 
(Table 2, Figure 2).
Brain lesions 
Brain edema was commonly absent, though celecoxib-
treated rats presented with damaged (balloonized) red 
neurons without any inflammation that were markedly 
expressed particularly in the cerebral cortex and in the 
Purkinje cells (Table 3, Figure 3). At 48 h, these lesions 
were attenuated by L-arginine, but when combined 
with L-NAME, the beneficial effect of L-arginine was 
decreased to the control values. Treatment with L-NAME 
by itself, however, did not affect the extent of the 
celecoxib-brain lesions. Again, BPC 157 presented a 
stronger beneficial effect; alone, it completely alleviated 
celecoxib-induced brain lesions, both at 24 h and 48 h. 
Likewise, given together with other agents, BPC 157 
consistently demonstrated the same beneficial effect.
DISCUSSION
This study argues that the celecoxib-induced stomach, 
liver and brain lesions resulting from extended COX-2 
half of the mucosal thickness to full-blown ulcers; 
the defect bed was debris-covered, partially by 
erythrocytes, and it was surrounded by an edematous 
lamina propria with polymorphonuclear infiltration) 
showed a gradual increase from 24 h to 48 h after 
administration, while the liver and brain lesions showed 
sustained levels (Table 1, Figure 1). 
Only when these lesions became stronger, at the 
48 h mark after celecoxib, were they aggravated 
by L-NAME and attenuated by L-arginine. When 
combined, the beneficial effect of L-arginine completely 
overrode the damaging effect of L-NAME. BPC 157 
presented a stronger beneficial effect. Illustratively, 
given immediately after celecoxib, BPC 157 (in either 
of the regimens) completely alleviated the lesions 
induced by celecoxib, both at 24 h and 48 h. Likewise, 
when given together with other agents, BPC 157 
consistently demonstrated the same beneficial effect.
Liver lesions 
Celecoxib induced marked steatosis, congestion and 
necrosis at 24 h and at 48 h, along with increased 
enzyme serum values. The lesions were markedly 
attenuated by L-arginine at 24 h and at 48 h. Its 
beneficial effect was preserved at 24 h but decreased 
to control values at 48 h when combined with L-NAME, 
though L-NAME by itself could not affect celecoxib-
Medication (/kg intraperitoneally) immediately after celecoxib 1 
g/kg intraperitoneally
Sum of longest lesions diameters (means ± SD, mm) assessed rafter celecoxib and 
mediation application
24 h 48 h
Control, saline 5 ml 10 ± 2   17 ± 3.5
BPC 157 10 µg    0 ± 0a   7.5 ± 2.8a
BPC 157 10 ng       2 ± 0.8a      4 ± 1.2a
BPC 157 1 ng    2.2 ± 0.6a 4.3 ± 1a
l-NAME 5 mg 13 ± 2 30 ± 5a
l-arginine 100 mg      7 ± 1.5    5 ± 1a
l-NAME 5 mg + l-arginine 100 mg   8 ± 2 10 ± 3a
l-NAME 5 mg + BPC 157 10 µg    2 ± 1a   4 ± 2a
l-NAME 5 mg + BPC 157 10 ng    3.2 ± 0.8a      5 ± 0.6a
l-arginine 100 mg + BPC 157 10 µg       1 ± 0.5a    2.5 ± 0.8a
l-arginine 100 mg + BPC 157 10 ng    2.3 ± 0.4a    4.5 ± 0.6a
l-NAME 5 mg + l-arginine 100 mg + BPC 157 10 µg       1 ± 0.5a    2.5 ± 0.6a
l-NAME 5 mg + l-arginine 100 mg + BPC 157 10 ng    2.5 ± 0.4a    4.7 ± 0.7a
Table 1  Gastric lesions assessment after celecoxib, BPC 157, L-NAME, L-arginine
aP < 0.05 vs control.
BPC 157
Control L-NAME
L-arginine
Figure 1  Gross presentation of celecoxib-induced gastric lesions at 48 h. 
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inhibition are a function of NO system dysfunction, 
which is particularly worsened after a high-dose 
application. Considering the advanced safety profile 
of celecoxib[10], lower celecoxib regimens such as 
200 mg/kg and 500 mg/kg given intraperitoneally 
were without notable effect on gastric, liver or brain 
lesions (thus, these results are not specifically shown). 
These lesions could be all influenced by the NOS 
substrate L-arginine and in particular by the stable 
pentadecapeptide BPC 157, which is an agent known to 
counteract non-selective NSAID-induced ulcerogenesis 
as well as the liver and brain lesions that interact 
with the NO system[1,9]. The additional support comes 
from the similar therapy effects obtained with the 
correspondingly high dose range of BPC 157 therapy, 
which was similar to the dosing used in other studies as 
well[33,34].
This study argues that the celecoxib-induced stomach, 
liver and brain lesions presenting after COX-2 inhibition 
demonstrate a particular NO system dysfunction. These 
effects could be all influenced by the NOS substrate 
L-arginine, particularly by the stable pentadecapeptide 
BPC 157, which is an agent known to counteract non-
selective NSAID-induced ulcerogenesis as well as liver 
and brain lesions and particularly interacts with the NO 
system[1,9]. 
Medication (/kg intraperitoneally) 
immediately after celecoxib 1 g/kg 
intraperitoneally
Time after 
celecoxib
Liver lesions assessment
Microscopic assessment, Score (0-3), Min/Med/Max Serum enzymes values (IU/L), means ± SD
steatosis congestion necrosis ALT AST
Control, saline 5 ml 24 h 2/2/3 2/2/3 2/2/3  352 ± 12 75 ± 8
48 h 2/3/3 2/2/3 2/2/3  356 ± 18 84 ± 9
BPC 157 10 µg 24 h  1/1/1a  1/1/2a  1/1/1a   138 ± 14a    41 ± 11a
48 h  1/1/1a  1/1/2a  1/1/1a     63 ± 12a    35 ± 12a
BPC 157 10 ng 24 h  1/1/1a  1/1/2a  1/1/1a   154 ± 13a  45 ± 8a
48 h  1/1/2a  1/1/2a  1/1/1a     72 ± 19a  40 ± 7a
BPC 157 1 ng 24 h  1/1/1a  1/1/2a  1/1/1a   170 ± 15a    48 ± 10a
48 h  1/1/2a  1/1/2a  1/1/1a     80 ± 15a  43 ± 8a
l-NAME 5 mg 24 h 2/3/3 2/2/3 2/2/3  375 ± 11   86 ± 12
48 h 3/3/3 2/3/3 2/2/3  400 ± 12   80 ± 10
l-arginine 100 mg 24 h  1/2/2a  1/2/2a  1/2/2a   315 ± 14a    68 ± 14a
48 h  1/2/2a  1/2/2a  1/2/2a   300 ± 21a    65 ± 10a
l-NAME 5 mg + l-arginine 100 mg 24 h  1/2/2a  1/2/2a  1/2/2a   293 ± 17a  68 ± 9a
48 h 2/2/2 2/2/3 2/2/2   270 ± 15a    73 ± 11a
l-NAME 5 mg + BPC 157 10 µg 24 h  1/1/1a  1/2/2a  1/1/1a   170 ± 15a  69 ± 9a
48 h  1/1/2a  1/2/2a  1/1/1a   150 ± 12a    55 ± 13a
l-NAME 5 mg + BPC 157 10 ng 24 h  1/1/1a  1/2/2a  1/1/1a   210 ± 16a  70 ± 7a
48 h  1/1/2a  1/2/2a  1/1/1a   182 ± 14a  60 ± 8a
l-arginine 100 mg + BPC 157 10 µg 24 h  1/1/1a  1/1/1a  1/1/1a   165 ± 25a  55 ± 8a
48 h  1/1/2a  1/1/1a  1/1/1a   160 ± 18a  45 ± 8a
l-arginine 100 mg + BPC 157 10 ng 24 h  1/1/1a  1/1/2a  1/1/1a   190 ± 11a    63 ± 10a
48 h  1/1/2a  1/1/2a  1/1/1a   170 ± 13a  55 ± 9a
l-NAME 5 mg + l-arginine 100 mg 
+ BPC 157 10 µg
24 h  1/1/2a  1/1/2a  1/1/1a   167 ± 11a    57 ± 10a
48 h  1/1/2a  1/1/2a  1/1/1a   176 ± 14a  57 ± 8a
l-NAME 5 mg + l-arginine 100 mg 
+ BPC 157 10 ng
24 h  1/1/2a  1/1/2a  1/1/1a 202 ± 9a  62 ± 7a
48 h  1/1/2a  1/1/2a  1/1/1a   190 ± 12a  65 ± 8a
Table 2  Liver lesions assessment after celecoxib, BPC 157, L-NAME, L-arginine
aP < 0.05 vs control.
Figure 2  Presentation of celecoxib-induced liver lesions at 48 h. Controls presented with pronounced microvesicullar and macrovesicullar steatosis, dilated 
sinusoids, and piecemeal necrosis (A); BPC 157 rats presenting with minimal microvesicullar steatosis and no necrosis (B). HE × 40.
A B
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In support of this argument, the evidence for non-
selective NSAIDs[5-8] shows that they cause more 
gastrointestinal lesions, more liver toxicity, and more 
toxicity in the brain due to the known COX-1/COX-2 
relationship[5-8]. 
On the other hand, after celecoxib treatment, the 
deleterious course that characterizes COX-2 inhibition 
should be more complex. This course includes initial 
stomach lesions and further progressing lesions that 
deteriorate over time as well as extensive liver and 
brain lesions that are already sustainably present 
at the early 24 h period. Further, these lesions are 
reciprocally potentiated by L-NAME and opposed by 
L-arginine in a particular way. 
In so doing and in substantiating the particularities 
for the initial lesions in the stomach at 24 h, it is 
likely that celecoxib provides COX-2 inhibition; at that 
time, in the stomach, there is no effect of L-arginine 
or L-NAME. However, the liver and brain lesions likely 
appear due to COX-2 inhibition and NOS dysfunction, 
the latter of which is counteracted by L-arginine. 
Next, in addition to this opposing effect of L-arginine, 
NOS blockade specifically contributes NOS dysfunction 
to COX-2 inhibition as verified over the 24-48 h period. 
Medication (/kg intraperitoneally) 
immediately after celecoxib 1 g/kg 
intraperitoneally
Time after 
celecoxib
Brain lesions assessment
Microscopic assessment, Score (0-4), 
Min/Med/Max
Microscopic assessment, Score (0-3), 
Min/Med/Max
Purkinje cells (red neurons) Cerebral cortex (red neurons) Edema
Control, saline 5 ml 24 h 2/2/2 2/2/2 0/0/0
48 h 2/2/3 2/2/3 0/0/0
BPC 157 10 µg 24 h  0/0/0a  0/1/1a 0/0/0
48 h  0/1/1a  0/1/1a 0/0/0
BPC 157 10 ng 24 h  0/1/1a  0/1/1a 0/0/0
48 h  0/1/1a  1/1/1a 0/0/0
BPC 157 1 ng 24 h  0/1/1a  0/1/1a 0/0/0
48 h  0/1/1a  0/1/1a 0/0/0
l-NAME 5 mg 24 h 2/2/3 2/2/3 0/0/0
48 h 2/3/3 2/3/3 0/0/0
l-arginine 100 mg 24 h 1/2/2 1/2/2 0/0/0
48 h  1/2/2a  1/2/2a 0/0/0
l-NAME 5 mg + l-arginine 100 mg 24 h 2/2/2 2/2/2 0/0/0
48 h 2/2/2 2/2/2 0/0/0
l-NAME 5 mg + BPC 157 10 µg 24 h  1/1/1a  1/1/2a 0/0/0
48 h  1/1/2a  1/1/2a 0/0/0
l-NAME 5 mg + BPC 157 10 ng 24 h  1/1/1a  1/1/2a 0/0/0
48 h  1/1/2a  1/1/2a 0/0/0
l-arginine 100 mg+ BPC 157 10 µg 24 h  0/1/1a  0/1/1a 0/0/0
48 h  1/1/2a  0/1/1a 0/0/0
l-arginine 100 mg + BPC 157 10 ng 24 h  0/1/1a  0/1/1a 0/0/0
48 h  1/1/2a  1/1/1a 0/0/0
l-NAME 5 mg + l-arginine 100 mg + 
BPC 157 10 µg
24 h  1/1/2a  1/1/1a 0/0/0
48 h  1/1/2a  1/1/1a 0/0/0
l-NAME 5 mg + l-arginine 100 mg + 
BPC 157 10 ng
24 h  1/1/2a  1/1/1a 0/0/0
48 h  1/1/2a  1/2/1a 0/0/0
Table 3  Brain lesions assessment after celecoxib, BPC 157, L-NAME, L-arginine 
aP < 0.05 vs control.
Figure 3  Presentation of celecoxib-induced cerebral cortex lesions at 48 h. Control celecoxib rats presented more damaged (balloonized) red neurons without 
any inflammation markedly expressed in particular in the cerebral cortex (A), unlike BPC 157 + celecoxib rats (B). HE × 40.
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It is only in competition with the progressive stomach 
lesions that the beneficial effect of L-arginine occurs. 
Similarly, L-NAME aggravation occurs in stomach 
lesions, while the liver and brain lesions cannot not be 
worsened further. Therefore, maximal NOS dysfunction 
with COX-2 inhibition is present in the brain more than 
in the liver. Namely, unlike stomach lesions (where 
L-arginine nullifies L-NAME aggravation) and liver 
lesions, in brain lesions, L-arginine could not work to 
counteract an L-NAME-induced NOS blockade.
Thus, there is threefold confirmation of the NO 
relationship: L-NAME (NOS blockade) in stomach 
lesions; L-arginine (NOS substrate) counteracts 
stomach, liver, brain lesions; and L-arginine and L-NAME 
could specifically affect each other’s response in the 
stomach, liver and brain. 
Finally, for all these lesions in the stomach, liver and 
brain, celecoxib- and/or L-NAME-induced lesions were 
completely inhibited by BPC 157 administration. As 
mentioned, BPC 157, due to its counteraction of NSAID-
induced lesions[1] and interaction with NO agents[1,9], 
is assumed to be more prone to counteracting both 
COX-1/COX-2 and NOS inhibition than L-arginine as an 
NOS substrate. In addition, this result is also true for 
COX-2/NOS inhibition. Further, BPC 157 induces NO 
release from the gastric mucosa supernatant, similarly 
to L-arginine[35], but it also functions under conditions 
where L-arginine does not work[36]. This mechanism 
assumes a persistent, beneficial effect versus increasing 
dysfunction of the nitrergic pathway (for instance, 
heavier loss of endothelium cells from the vascular wall 
could lead to less NO production ability[37]), making 
COX-2/NOS inhibition worse as the tissue integrity is 
damaged further. Likely as a result of this relationship, 
the same effectiveness is observed in all increasingly 
damaged circumstances following celecoxib and 
L-NAME application. This process specifically involves 
all BPC 157 groups when administered with celecoxib 
alone and/or with NO agents (L-arginine + BPC 157; 
L-NAME + BPC 157; L-NAME + L-arginine + BPC 157) 
in the stomach, liver and brain. BPC 157 may thereby 
equally counteract both COX-2 inhibition (counteracting 
the noxious effects of celecoxib on all lesions) and 
additional NOS blockade (equally counteracting 
the noxious effects of celecoxib + L-NAME)[1,9]. This 
outcome occurs equally with either µg- or ng dosing 
regimens. In addition, BPC 157 affects eNOS gene 
function as well[38] as that of other genes[38-42]. 
In the latter cases, in the healing process, BPC-157 
regulates the phosphorylation level of extracellular 
signal-regulated kinases 1 and 2 (ERK1/2) as well 
as their downstream targets, including c-Fos, c-Jun, 
and egr-1, key molecules involved in cell growth, 
migration, and angiogenesis[38-42]. 
In conclusion, the therapy and syndrome in rats 
treated with celecoxib described herein (the gastro-
intestinal tract, liver and brain lesions presented 
rapidly in rats) overlaps with the definitive follow-up 
of previous non-selective NSAID studies[1,5-8]. With 
respect to the administration of pentadecapeptide BPC 
157, these results extend and generalize the observed 
acute and long-term therapeutic effects[5-8]. Then, over 
longer periods, there is greater deterioration from 
celecoxib, the COX-2-inhibitor, and the NO synthetase 
(NOS)-blocker L-NAME when combined, along with 
prominent rescue by the stable pentadecapeptide 
BPC 157 and less prominent attenuation with the 
NOS substrate L-arginine. These findings should likely 
reveal an aggravating parallelism between COX-2 and 
NOS inhibition[43], including the role of the NO system 
in gastrointestinal[2,3] and liver damage and hepatic 
encephalopathy[4] as well as celecoxib syndrome in 
particular NO system pathways.
Conclusively, L-arginine, but more so BPC 157, 
may provide a particular therapy that may alleviate 
likely gastrointestinal, liver and brain lesions and 
redress NSAIDs’ post-surgery application and NO 
system involvement. However, the particular point 
remains that a single large overdose challenge differs 
considerably from the lower regular patient regimens 
throughout a markedly more prolonged treatment 
duration. 
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